Dianthus Therapeutics announced Q1 2026 financial results and key business updates, including an early go decision in their Phase 3 CAPTIVATE trial for claseprubart in CIDP after achieving 20 responders early. The company is on track to start a Phase 3 trial for generalized Myasthenia Gravis mid-2026 and expects top-line results by late 2028. They also continue Phase 2 trials for Multifocal Motor Neuropathy and Phase 1 trials for DNTH212 targeting rheumatology diseases. Dianthus strengthened its cash position to approximately $1.2 billion after raising $719 million in a public offering, providing runway into 2030. These developments position Dianthus to advance its pipeline of next-generation autoimmune therapies.
Okta reported better-than-expected Q1 results with EPS of $1.05 and revenue of $805 million, driven by high demand for AI security solutions. The company’s new AI products now account for 30% of total bookings, fueling growth in the competitive cyber...
Shares of Cre8 Enterprise Limited (CRE) surged nearly 165% after reporting a record 550 customers and a 482% rise in IPO filings in H1 2026. Abercrombie & Fitch (ANF) jumped over 35% following stronger-than-expected quarterly results and raised guida...
Greenland Mines Ltd. shares dropped nearly 50% after announcing a $20 million public offering, raising dilution concerns. Qfin Holdings saw an 18.9% decline following weaker Q2 revenue and sharply lower profits despite beating earnings expectations. ...
Olivia Nottebohm, Chief Operating Officer of Box, sold 5,834 shares of the company, generating $188,500 from the transaction. This insider sale could indicate personal financial planning or a shift in confidence, but without further context, its impa...
J.M. Smucker reported a strong first quarter with adjusted earnings of $3.24 per share, a 71% increase year-over-year, and revenue of $2.2 billion, beating analyst expectations. The company showed robust financial health with free cash flow of $337.3...
